Literature DB >> 1090224

Host failure in treatment of malaria with sulfalene and pyrimethamine.

G M Trenholme, R L Williams, H Frischer, P E Carson, K H Rieckmann.   

Abstract

An individual infected with a multidrug-resistant strain of Plasmodium falciparum failed to respond to treatment with sulfalene and pyrimethamine. Subinoculation studies showed that parasite resistance to the drug combination was not present. Plasma levels of sulfalene and pyrimethamine in this individual were similar to those of three individuals, subinoculated from him, who were cured by the drug combination. Erythrocyte levels of sulfalene in this individual were similar to those in an individual, subinoculated from him, who was cured by the drug combination. After treatment with the drug combination, in vitro tests showed similar antimalarial activity in the serum of this individual in comparison with the serum of this individual in comparison with the serum of an individual subinoculated from him. The failure of this individual to respond to treatment with sulfalene and pyrimethamine is attributed to an undefined host factor (or factors) that appear(s) to be present in his erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090224     DOI: 10.7326/0003-4819-82-2-219

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  In vitro activities of and mechanisms of resistance to antifol antimalarial drugs.

Authors:  W K Milhous; N F Weatherly; J H Bowdre; R E Desjardins
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

2.  A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya.

Authors:  H C Spencer; W M Watkins; D G Sixsmith; D K Koech; J D Chulay
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

3.  Chloroquine-resistant falciparum malaria imported into the Netherlands.

Authors:  J C Wetsteyn; A de Geus
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.